Respiratory News and Research

RSS

New data highlights urgent need for better asthma care – How FeNO testing can help reduce hospitalizations

Bedfont® calls for wider FeNO testing adoption to improve asthma care, reduce emergency visits, and ensure timely treatment for better respiratory health.

From NObreath 9 Apr 2025

New drug compound offers pain relief without opioid side effects

University of Florida scientists have helped identify a novel drug compound that selectively activates pain-altering receptors in the body, offering a potentially safer alternative to conventional pain medications.

8 Apr 2025

Blood test breakthrough pinpoints 70 proteins linked to asthma risk in major genetic study

Researchers used UK Biobank data to identify 70 proteins with genetically predicted roles in asthma, offering insights into disease mechanisms.

7 Apr 2025

New guidelines aim to improve diagnosis and treatment of mycoplasma pneumoniae in children

The Chinese Medical Association has released new guidelines for diagnosing and treating Mycoplasma pneumoniae in children.

7 Apr 2025

Exposure to wildfire smoke raises mental health visits to emergency departments

Exposure to fine particulate air pollution (PM2.5) from wildfire smoke was associated with increased visits to emergency departments (ED) for mental health conditions, according to a new study led by researchers at Harvard T.H. Chan School of Public Health.

4 Apr 2025

Cedars-Sinai study reveals distinct roles for AI and physicians in virtual care

Do physicians or artificial intelligence (AI) offer better treatment recommendations for patients examined through a virtual urgent care setting? A new Cedars-Sinai study shows physicians and AI models have distinct strengths.

4 Apr 2025

Enhanced tuberculosis detection in advanced HIV using stool molecular testing

The Xpert MTB/Ultra molecular diagnostic test for stool samples, until now recommended only for children, could be established as an additional test for diagnosing tuberculosis in adults living with HIV.

4 Apr 2025

Rutgers researchers develop promising new oral antiviral for COVID-19

Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment.

3 Apr 2025

Shingles vaccine cuts dementia risk by 20%, new study shows

A large natural experiment shows that the herpes zoster vaccine reduces dementia diagnoses by 20% over seven years. The findings suggest both viral suppression and immune training may play roles in brain health.

3 Apr 2025

New CT-based score helps predict need for repeat sinus surgery

A new CT-scan based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to chronic rhinosinusitis.

3 Apr 2025

Study exposes huge levels untargeted antibiotic prescribing

Doctors are prescribing antibiotics for tens of thousands of patients with infections, with little or no consideration of prognosis and the risk of the infection worsening, according to a new study led by University of Manchester epidemiologists.

3 Apr 2025

Pregnancy linked to lower long COVID risk in study of over 70,000 women

Pregnant women who contract SARS-CoV-2 may have a lower risk of developing Long COVID than matched non-pregnant women.

2 Apr 2025

How much will that surgery cost? 🤷 Hospital prices remain largely unhelpful.

It's a holy grail of health care: forcing the industry to reveal prices negotiated between health plans and hospitals — information that had long been treated as a trade secret.

2 Apr 2025

Bedfont® Scientific Limited highlights FeNO testing’s role in childhood asthma for World Health Day 2025

As the world prepares to observe World Health Day on April 7th, 2025, Bedfont® Scientific Limited highlights the importance of early and accurate asthma diagnosis with its innovative NObreath® Fractional exhaled Nitric Oxide (FeNO) device.

From NObreath 2 Apr 2025

WINREVAIR™ (sotatercept-csrk) reduced the risk of a composite of all-cause death, lung transplantation and hospitalization for pulmonary arterial hypertension (PAH) by 76% compared to placebo in the phase 3 ZENITH trial

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR™ (sotatercept-csrk) compared to placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality who were on maximum tolerated background PAH therapy. At a median follow-up of 10.6 months (range, 0.3-26.1), WINREVAIR reduced the relative risk of major morbidity and mortality events (the composite of all-cause death, lung transplantation and PAH worsening-related hospitalization of ≥24 hours) by 76% (HR=0.24 [95% CI, 0.13-0.43]; p<0.0001 [1-sided]) compared to placebo.

1 Apr 2025

Does COVID-19 affect heart rate variability after recovery?

Researchers determine the impact of mild COVID-19 on heart rate variability.

31 Mar 2025

Owlstone Medical secures investment from Cystic Fibrosis Foundation

Owlstone Medical ("Owlstone"), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced that the Cystic Fibrosis Foundation has made an up to USD $2.3 million equity investment (circa £1.7 million) in Owlstone to develop a breath test for Pseudomonas aeruginosa (PA) detection in patients with cystic fibrosis (CF).

29 Mar 2025